Terms: = Lung cancer AND TRIM33, RFG7, 51592, ENSG00000197323, Q9UPN9, TF1G, FLJ32925, TIF1G, PTC7, TIFGAMMA, TIF1GAMMA AND Diagnosis
8 results:
1. Clinical, histologic and prognostic features of clinically amyopathic dermatomyositis.
Fornaro M; Girolamo F; Giannini M; Coladonato L; Capuano A; Capodiferro M; D'Abbicco D; Ruggieri M; Mastrapasqua M; Iannone F
Clin Exp Rheumatol; 2024 Feb; 42(2):288-294. PubMed ID: 38488091
[TBL] [Abstract] [Full Text] [Related]
2. Myositis autoantibodies in Iranian myositis patients: assessment the frequency and clinical relevancy.
Ebrahimi M; Rostamian A; Rafiei-Latianee R; Najafizadeh SR; Movaseghi S; Faezi ST; Ghazanfari T
Clin Rheumatol; 2022 Feb; 41(2):533-539. PubMed ID: 34514533
[TBL] [Abstract] [Full Text] [Related]
3. The Combination of IgA and IgG autoantibodies against Transcriptional Intermediary Factor-1γ contributes to the early diagnosis of lung cancer.
Yu L; Lin X; Zhang L; Wu Q; Zhang S; Chen D; Pan X; Huang Y
Int J Med Sci; 2020; 17(11):1561-1568. PubMed ID: 32669959
[No Abstract] [Full Text] [Related]
4. Coexisting TIF1γ-positive Primary Pulmonary Lymphoepithelioma-like Carcinoma and Anti-TIF1γ Antibody-positive Dermatomyositis.
Nakanishi Y; Yamaguchi K; Yoshida Y; Sakamoto S; Horimasu Y; Masuda T; Nakashima T; Miyamoto S; Iwamoto H; Hirata S; Fujitaka K; Hamada H; Sugiyama E; Hattori N
Intern Med; 2020 Oct; 59(20):2553-2558. PubMed ID: 32581161
[TBL] [Abstract] [Full Text] [Related]
5. Integration of IgA and IgG Autoantigens Improves Performance of Biomarker Panels for Early diagnosis of lung cancer.
Pan J; Yu L; Wu Q; Lin X; Liu S; Hu S; Rosa C; Eichinger D; Pino I; Zhu H; Qian J; Huang Y
Mol Cell Proteomics; 2020 Mar; 19(3):490-500. PubMed ID: 31924693
[TBL] [Abstract] [Full Text] [Related]
6. [Dermatomyositis: new antibody, new classification].
Bolko L; Gitiaux C; Allenbach Y
Med Sci (Paris); 2019 Nov; 35 Hors série n° 2():18-23. PubMed ID: 31859626
[TBL] [Abstract] [Full Text] [Related]
7. Small Cell lung cancer Patient with Anti-transcriptional Intermediary Factor 1γ Antibody Who Developed Dermatomyositis after Successful Chemoradiotherapy.
Aritomi T; Kido T; Nakano K; Satoh Y; Noguchi S; Jotatsu T; Hanaka T; Satoh M; Tanaka Y; Yatera K
Intern Med; 2019 Feb; 58(3):427-431. PubMed ID: 30210109
[TBL] [Abstract] [Full Text] [Related]
8. Autoantibodies against TIF-1-γ and CADM-140 in Spanish patients with clinically amyopathic dermatomyositis (CADM): clinical significance and diagnostic utility.
Cuesta-Mateos C; Colom-Fernández B; Portero-Sainz I; Tejedor R; García-García C; Concha-Garzón MJ; De las Heras-Alonso ME; Martínez MA; Juarez C; Muñoz-Calleja C
J Eur Acad Dermatol Venereol; 2015 Mar; 29(3):482-9. PubMed ID: 25065441
[TBL] [Abstract] [Full Text] [Related]
